Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial.

Mark Krogh Hvistendahl Rahim Mohammad NaimiSvend Høime HansenJens Frederik RehfeldHannelouise KissowJens PedersenLars Ove DragstedDavid Peick SonneFilip Krag KnopPalle Bekker Jeppesen

Published in: JPEN. Journal of parenteral and enteral nutrition (2021)

Glepaglutide may stimulate the bile acid/FXR/FGF19 axis, leading to increased plasma concentrations of FGF19. Thereby, glepaglutide may ameliorate the accelerated de novo bile acid synthesis and play a role in the prevention and/or treatment of intestinal failure-associated liver disease.

Keyphrases

double blind
open label
placebo controlled
phase iii
clinical trial
randomized controlled trial
combination therapy
binding protein
replacement therapy